Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Dec 2018: Trial registered, NCT03768063
  2. 28 Feb 2019: Trial started, NCT03768063

The trials

NCT03768063: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

State
Under way
Phase
Phase 3
People
1,000 planned
Started
28 Feb 2019
Primary completion
5 Jul 2028
Arms
Combined Agents with Atezolizumab
Results
None posted
  1. 7 Dec 2018: Trial registered
  2. 28 Feb 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.